WO2003020884A3 - Method for rapid generation of mature dendritic cells - Google Patents

Method for rapid generation of mature dendritic cells Download PDF

Info

Publication number
WO2003020884A3
WO2003020884A3 PCT/US2002/025732 US0225732W WO03020884A3 WO 2003020884 A3 WO2003020884 A3 WO 2003020884A3 US 0225732 W US0225732 W US 0225732W WO 03020884 A3 WO03020884 A3 WO 03020884A3
Authority
WO
WIPO (PCT)
Prior art keywords
mature dendritic
dendritic cells
dendritic cell
rapid generation
methods
Prior art date
Application number
PCT/US2002/025732
Other languages
French (fr)
Other versions
WO2003020884A2 (en
Inventor
Dennis M Klinman
Mayda Gursel
Daniela Verthelyi
Original Assignee
Us Health
Dennis M Klinman
Mayda Gursel
Daniela Verthelyi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health, Dennis M Klinman, Mayda Gursel, Daniela Verthelyi filed Critical Us Health
Priority to AU2002361468A priority Critical patent/AU2002361468A1/en
Priority to US10/486,755 priority patent/US7354909B2/en
Publication of WO2003020884A2 publication Critical patent/WO2003020884A2/en
Publication of WO2003020884A3 publication Critical patent/WO2003020884A3/en
Priority to US12/058,213 priority patent/US7959934B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/46482—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/056—Immunostimulating oligonucleotides, e.g. CpG

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel methods for rapidly generating dendritic cells are disclosed herein. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one specific, non/limiting example, the method includes contacting the dendritic cell precursor or the mature dendritic cell with an antigen. The methods are of use both in vitro and $i(in vivo.)
PCT/US2002/025732 2001-08-14 2002-08-13 Method for rapid generation of mature dendritic cells WO2003020884A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002361468A AU2002361468A1 (en) 2001-08-14 2002-08-13 Method for rapid generation of mature dendritic cells
US10/486,755 US7354909B2 (en) 2001-08-14 2002-08-13 Method for rapid generation of mature dendritic cells
US12/058,213 US7959934B2 (en) 2001-08-14 2008-03-28 Method for rapid generation of mature dendritic cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31219001P 2001-08-14 2001-08-14
US60/312,190 2001-08-14

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10486755 A-371-Of-International 2002-08-13
US12/058,213 Continuation US7959934B2 (en) 2001-08-14 2008-03-28 Method for rapid generation of mature dendritic cells

Publications (2)

Publication Number Publication Date
WO2003020884A2 WO2003020884A2 (en) 2003-03-13
WO2003020884A3 true WO2003020884A3 (en) 2004-09-16

Family

ID=23210279

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/025732 WO2003020884A2 (en) 2001-08-14 2002-08-13 Method for rapid generation of mature dendritic cells

Country Status (3)

Country Link
US (2) US7354909B2 (en)
AU (1) AU2002361468A1 (en)
WO (1) WO2003020884A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871732B2 (en) 2002-12-23 2014-10-28 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (en) 1999-04-12 2013-04-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Oligodeoxynucleotide and its use to induce an immune response
ATE378348T1 (en) * 2000-01-14 2007-11-15 Us Health OLIGODEOXYNUCLEOTIDES AND THEIR USE FOR INDUCING AN IMMUNE RESPONSE
US20030129251A1 (en) * 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
KR100917101B1 (en) * 2000-08-04 2009-09-15 도요 보세키 가부시키가이샤 Flexible metal laminate and production method thereof
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
EP2423335B1 (en) * 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
AU2002366710A1 (en) * 2001-12-20 2003-07-09 The Government Of The United States Of America As Represented By The Secretary Of The Department Of USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) * 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) * 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
JP3725104B2 (en) * 2002-08-29 2005-12-07 株式会社東芝 Information recording medium and information recording apparatus
US7956043B2 (en) * 2002-12-11 2011-06-07 Coley Pharmaceutical Group, Inc. 5′ CpG nucleic acids and methods of use
CN1867355A (en) * 2003-08-11 2006-11-22 财团法人阪大微生物病研究会 New vaccine containing mucosa immunity-inducing adjuvant
AU2004275876B2 (en) * 2003-09-25 2011-03-31 Coley Pharmaceutical Gmbh Nucleic acid-lipophilic conjugates
CN101454451A (en) * 2003-10-30 2009-06-10 科勒制药有限公司 C-class oligonucleotide analogs with enhanced immunostimulatory potency
WO2006065751A2 (en) * 2004-12-13 2006-06-22 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
WO2007070660A2 (en) 2005-12-13 2007-06-21 President And Fellows Of Harvard College Scaffolds for cell transplantation
AR060424A1 (en) * 2007-04-11 2008-06-18 Consejo Nac Invest Cient Tec CELLULAR LINES, COMPOSITIONS FOR THE TREATMENT OF MELANOMS THAT UNDERSTAND PROCEDURES TO PREPARE COMPOSITIONS AND TREATMENT METHODS
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
CN102006891B (en) 2008-02-13 2017-04-26 哈佛学院董事会 Continuous cell programming devices
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
CN104056261B (en) 2008-04-17 2017-01-11 海莱乌医院 Indoleamine 2, 3-dioxygenase based immunotherapy
US9012399B2 (en) 2008-05-30 2015-04-21 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
KR101881596B1 (en) 2008-12-02 2018-07-24 웨이브 라이프 사이언시스 재팬 인코포레이티드 Method for the synthesis of phosphorous atom modified nucleic acids
NZ593220A (en) 2008-12-09 2012-10-26 Coley Pharm Group Inc Immunostimulatory oligonucleotides
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
SG177564A1 (en) 2009-07-06 2012-02-28 Ontorii Inc Novel nucleic acid prodrugs and methods of use thereof
US8467973B2 (en) * 2009-07-28 2013-06-18 Promising Future, Llc Pairing processes for preparing alloreactive cytotoxic T cells
JP5926180B2 (en) 2009-07-31 2016-05-25 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Methods of cell programming for tolerogenic therapy
AU2010307075B2 (en) 2009-10-12 2014-12-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Granulysin in immunotherapy
EP2542230A4 (en) 2010-03-05 2013-08-28 Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
EP2585053A4 (en) 2010-06-25 2014-02-26 Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
WO2012039448A1 (en) 2010-09-24 2012-03-29 株式会社キラルジェン Asymmetric auxiliary group
PT2624873T (en) 2010-10-06 2020-03-04 Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012148684A1 (en) 2011-04-27 2012-11-01 President And Fellows Of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
ES2878089T3 (en) 2011-04-28 2021-11-18 Harvard College Injectable preformed macroscopic three-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
EP2734208B1 (en) 2011-07-19 2017-03-01 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
ES2773895T3 (en) 2012-04-16 2020-07-15 Harvard College Mesoporous Silica Compositions to Modulate Immune Responses
AU2013252785B2 (en) * 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
KR102213609B1 (en) 2012-07-13 2021-02-08 웨이브 라이프 사이언시스 리미티드 Chiral control
WO2014010718A1 (en) * 2012-07-13 2014-01-16 株式会社新日本科学 Chiral nucleic acid adjuvant
EP2872485B1 (en) 2012-07-13 2020-12-16 Wave Life Sciences Ltd. Asymmetric auxiliary group
WO2015108047A1 (en) 2014-01-15 2015-07-23 株式会社新日本科学 Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108046A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antiallergic agent having antiallergic action
JPWO2015108048A1 (en) 2014-01-15 2017-03-23 株式会社新日本科学 Chiral nucleic acid adjuvant and antitumor agent having antitumor activity
AU2015207773B2 (en) 2014-01-16 2021-06-17 Wave Life Sciences Ltd. Chiral design
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College Peritumoral and intratumoral materials for cancer therapy
CN107708756A (en) 2015-04-10 2018-02-16 哈佛学院院长等 Immunocyte acquisition equipment and its preparation and application
JP2018519262A (en) 2015-05-07 2018-07-19 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ Dendritic cell immunotherapy
EP3919507A3 (en) 2015-07-01 2022-01-12 Immatics Biotechnologies GmbH Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) * 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3411475A4 (en) 2016-02-06 2019-09-11 President and Fellows of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
US11020465B2 (en) 2016-03-04 2021-06-01 The Trustees Of Columbia University In The City Of New York Development of dual whole cell-based vaccine against pancreatic cancer
JP7185530B2 (en) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド Methods and compositions for promoting immune cell function
AU2017295704B2 (en) 2016-07-13 2023-07-13 President And Fellows Of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
CN111432836A (en) 2017-09-05 2020-07-17 转矩医疗股份有限公司 Therapeutic protein compositions and methods of making and using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061151A2 (en) * 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001051500A1 (en) * 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response

Family Cites Families (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2215233A (en) 1937-11-13 1940-09-17 Simon L Ruskin Iron compound of nucleotides and their organic hydrolytic decomposition products and method of making same
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
US3911117A (en) 1971-12-20 1975-10-07 Fredrik Ender Raw fish and iron chelated with glutamic or ribonucleic acid in a mink diet
US3914450A (en) 1973-04-09 1975-10-21 Anheuser Busch Concentrated extract of yeast and processes of making same
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
DE3280400D1 (en) 1981-10-23 1992-06-04 Molecular Biosystems Inc OLIGONUCLEOTIDES MEDICINE AND THEIR PRODUCTION METHOD.
ES507187A0 (en) 1981-11-16 1983-01-01 Union Ind Y Agro Ganader S A U PROCEDURE FOR OBTAINING AN ADDITIONAL HUMANIZED MILK OF NUCLEOTIDES FOR CHILD FEEDING.
JPS60126220A (en) 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc Nucleic acid component composition
US4741914A (en) 1984-11-13 1988-05-03 Ajinomoto Co., Inc. Flavor enhancing seasoning containing deodorized garlic extract and process
US4956296A (en) 1987-06-19 1990-09-11 Genex Corporation Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
JPS62275667A (en) 1986-05-22 1987-11-30 Ajinomoto Co Inc Production of seasoning with good body or food with enhanced good body
US4950652A (en) 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
US4963387A (en) 1987-05-20 1990-10-16 Chugai Seiyaku Kabushiki Kaisha Salt substitute and foodstuffs containing same
ES2007350A6 (en) 1987-05-29 1989-06-16 Ganadera Union Ind Agro Food products enriched with nucleosides and/or nucleotides and preparation thereof.
CA1339596C (en) 1987-08-07 1997-12-23 New England Medical Center Hospitals, Inc. Viral expression inhibitors
US5268365A (en) 1988-03-11 1993-12-07 Rudolph Frederick B Nucleotides, nucleosides, and nucleobases in immune function restoration enhancement or maintenance
CA1336174C (en) 1988-07-22 1995-07-04 Ronald Peter Potman Method for the preparation of a yeast extract said yeast extract, its use as a food flavour and a food composition comprising the yeast extract
US5231085A (en) 1988-10-31 1993-07-27 Sandoz Ltd. Compositions and methods for the enhancement of host defense mechanisms
US5786189A (en) 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
US5248670A (en) 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5234811A (en) 1991-09-27 1993-08-10 The Scripps Research Institute Assay for a new gaucher disease mutation
US6022853A (en) 1991-08-30 2000-02-08 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
EP0633929B1 (en) 1992-04-01 2004-03-03 The Rockefeller University METHOD FOR $i(IN VITRO) PROLIFERATION OF DENDRITIC CELL PRECURSORS AND THEIR USE TO PRODUCE IMMUNOGENS
EP0572735B1 (en) 1992-06-04 1998-11-25 VYSIS, Inc. Nucleic acid probes for the detection of Mycoplasma fermentans
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
JPH08504570A (en) 1992-10-05 1996-05-21 ハイブライドン インコーポレイテッド Therapeutic anti-HIV oligonucleotides and drugs
US5650156A (en) 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
WO1995001097A1 (en) 1993-06-30 1995-01-12 Board Of Regents, The University Of Texas System Nucleotide preparation and uses thereof in wound healing
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US20030109469A1 (en) 1993-08-26 2003-06-12 Carson Dennis A. Recombinant gene expression vectors and methods for use of same to enhance the immune response of a host to an antigen
US5849719A (en) 1993-08-26 1998-12-15 The Regents Of The University Of California Method for treating allergic lung disease
US5492899A (en) 1994-01-10 1996-02-20 Abbott Laboratories Infant nutritional formula with ribo-nucleotides
US5602109A (en) 1994-01-10 1997-02-11 Abbott Laboratories Method to enhance the immune system of a human
US5700590A (en) 1994-01-10 1997-12-23 Abbott Laboratories Nutritional formula with ribo-nucleotides
US5488039A (en) 1994-01-10 1996-01-30 Abbott Laboratories Method for the production of an enteral formula containing ribo-nucleotides
DE69517836T2 (en) 1994-03-18 2001-03-01 Ajinomoto Kk Protein-containing agent to improve the taste quality of food
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
CA2194761C (en) 1994-07-15 2006-12-19 Arthur M. Krieg Immunomodulatory oligonucleotides
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5591721A (en) 1994-10-25 1997-01-07 Hybridon, Inc. Method of down-regulating gene expression
US5614191A (en) 1995-03-15 1997-03-25 The United States Of America As Represented By The Department Of Health And Human Services IL-13 receptor specific chimeric proteins and uses thereof
US6428788B1 (en) 1995-03-15 2002-08-06 Penn State University Compositions and methods for specifically targeting tumors
JP3580900B2 (en) 1995-04-20 2004-10-27 ホクレン農業協同組合連合会 Food and feed containing, as an active ingredient, a composition mainly comprising a sugar containing an α-glucosidase inhibitor
US5612060A (en) 1995-05-25 1997-03-18 Alexander; J. Wesley Enhancement of transplant graft survival through nutritional immunomodulation and immunosuppressive therapy
US5976580A (en) 1995-06-07 1999-11-02 Novus International, Inc. Nutrient formulation and process for enhancing the health, livability, cumulative weight gain or feed efficiency in poultry and other animals
US20030219752A1 (en) 1995-12-07 2003-11-27 Diversa Corporation Novel antigen binding molecules for therapeutic, diagnostic, prophylactic, enzymatic, industrial, and agricultural applications, and methods for generating and screening thereof
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
GB9525902D0 (en) 1995-12-16 1996-02-21 Zeneca Ltd Fungus
EP0879284B1 (en) 1996-01-30 2009-07-29 The Regents of The University of California Gene expression vectors which generate an antigen specific immune response and methods of using the same
US20030078223A1 (en) 1996-01-30 2003-04-24 Eyal Raz Compositions and methods for modulating an immune response
US5895652A (en) 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
ATE292980T1 (en) 1996-10-11 2005-04-15 Univ California IMMUNO-STIMULATING OLIGONUCLEOTIDE CONJUGATES
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) * 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
CA2286210A1 (en) * 1997-04-18 1998-10-29 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Attenuated salmonella strain used as a vehicle for oral immunization
US20030104044A1 (en) * 1997-05-14 2003-06-05 Semple Sean C. Compositions for stimulating cytokine secretion and inducing an immune response
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US20040006034A1 (en) * 1998-06-05 2004-01-08 Eyal Raz Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CA2291483C (en) 1997-06-06 2012-09-18 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
JP3202658B2 (en) * 1997-06-20 2001-08-27 日本電気株式会社 Variable rate CDMA transmission power control method
US5922766A (en) 1997-07-02 1999-07-13 Acosta; Phyllis J. B. Palatable elemental medical food
EP1009413B1 (en) 1997-09-05 2007-02-14 The Regents Of The University Of California Use of immunostimulatory oligonucleotides for preventing or treating asthma
ES2284247T3 (en) 1998-04-03 2007-11-01 University Of Iowa Research Foundation METHODS AND PRODUCTS TO STIMULATE THE IMMUNITY SYSTEM USING OLIGONUCLEOTIDES AND IMMUNOTHERAPEUTIC CYTOQUINS.
PL345241A1 (en) 1998-05-06 2001-12-03 Upjohn Co Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20010034330A1 (en) 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
EP1832657B1 (en) * 1998-09-09 2012-10-24 Genzyme Corporation Methylation of plasmid vectors
US20020065236A1 (en) 1998-09-09 2002-05-30 Yew Nelson S. CpG reduced plasmids and viral vectors
US20020142974A1 (en) 1998-09-11 2002-10-03 Leonard D. Kohn Immune activation by double-stranded polynucleotides
DE69931377T2 (en) 1998-09-18 2007-05-10 Dynavax Technologies Corp., Berkeley PROCESS FOR TREATING IG-E ASSOCIATED DISEASES AND COMPOSITIONS FOR USE THEREOF IN THESE METHODS
CA2359636A1 (en) 1999-01-22 2000-07-27 Andrew W. Taylor Activation of regulatory t cells by alpha-melanocyte stimulating hormone
US6977245B2 (en) * 1999-04-12 2005-12-20 The United States Of America As Represented By The Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
DE60023300T2 (en) 1999-06-29 2006-07-06 Glaxosmithkline Biologicals S.A. USE OF CPG AS ADJUVANS FOR HIV PULP
US6514948B1 (en) * 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
AP1775A (en) * 1999-09-25 2007-08-28 Univ Iowa Res Found Immunostimulatory nucleic acids.
US20020091095A1 (en) 1999-12-13 2002-07-11 Phillips Nigel C. Modulation of Fas and FasL expression
US20020006403A1 (en) 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
AU3108001A (en) 2000-01-20 2001-12-24 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for inducing a th2 immune response
US6478641B2 (en) * 2000-01-20 2002-11-12 W. Bishop Jordan Transmission for driving counter-rotating propellers, lubrication system, and associated methods
AT409085B (en) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh PHARMACEUTICAL COMPOSITION FOR IMMUNULATING AND PRODUCING VACCINES
US6552006B2 (en) * 2000-01-31 2003-04-22 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US20030130217A1 (en) 2000-02-23 2003-07-10 Eyal Raz Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
EP1259264A4 (en) 2000-02-23 2005-08-31 Univ California Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
AU2001239873A1 (en) 2000-02-24 2001-09-03 The Board Of Trustees Of The Leland Stanford Junior University Adjuvant treatment by in vivo activation of dendritic cells
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
US20020107212A1 (en) 2000-03-10 2002-08-08 Nest Gary Van Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US7129222B2 (en) 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
US20020098199A1 (en) * 2000-03-10 2002-07-25 Gary Van Nest Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en) 2000-03-10 2003-07-10 Gary Van Nest Biodegradable immunomodulatory formulations and methods for use thereof
US20010046967A1 (en) 2000-03-10 2001-11-29 Gary Van Nest Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
AU2001249609A1 (en) * 2000-03-28 2001-10-08 Department Of Veterans Affairs Methods for increasing a cytotoxic T lymphocyte response in vivo
EP1278550A4 (en) 2000-04-07 2004-05-12 Univ California Synergistic improvements to polynucleotide vaccines
GB0009470D0 (en) * 2000-04-17 2000-06-07 Univ Southampton Materials and methods relating to immune responses to fusion proteins
US6893821B2 (en) * 2000-05-05 2005-05-17 The Regents Of The University Of California Agents that modulate DNA-PK activity and methods of use thereof
US6593511B1 (en) * 2000-05-12 2003-07-15 Bioseek, Inc. Models of chronic and acute inflammatory diseases
KR100799788B1 (en) * 2000-06-08 2008-01-31 인터셀 아게 Immunostimulatory oligodeoxynucleotides
WO2001097843A2 (en) 2000-06-22 2001-12-27 University Of Iowa Research Foundation Methods for enhancing antibody-induced cell lysis and treating cancer
US20020165178A1 (en) 2000-06-28 2002-11-07 Christian Schetter Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
JP5511117B2 (en) 2000-07-27 2014-06-04 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Vaccine for broad protection against diseases caused by Neisseria meningitidis
US7318928B2 (en) * 2000-08-01 2008-01-15 The Johns Hopkins University Molecular vaccine linking intercellular spreading protein to an antigen
US20020198165A1 (en) 2000-08-01 2002-12-26 Bratzler Robert L. Nucleic acids for the prevention and treatment of gastric ulcers
US7811592B2 (en) 2000-08-16 2010-10-12 Auburn University Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia
IL154557A0 (en) * 2000-08-25 2003-09-17 Yeda Res & Dev Methods of treatment or prevention of autoimmune diseases with cpg-containing polynucleotide
US20020091097A1 (en) 2000-09-07 2002-07-11 Bratzler Robert L. Nucleic acids for the prevention and treatment of sexually transmitted diseases
WO2002022809A2 (en) 2000-09-15 2002-03-21 Coley Pharmaceutical Gmbh PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
WO2002026757A2 (en) 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
CN101428006A (en) 2000-09-28 2009-05-13 诺华疫苗和诊断公司 Microparticle compositions and methods for the manufacture thereof
ES2260291T3 (en) * 2000-09-28 2006-11-01 Chiron Corporation MICROPARTICLES FOR THE ADMINISTRATION OF HETEROLOGICAL NUCLEIC ACIDS.
AU2002228932A1 (en) 2000-10-24 2002-05-06 Schering Corporation Maturation of dendritic cells
KR100331952B1 (en) * 2000-11-23 2002-04-09 최수일 The Composition Of Multipurpose High-Functional Alkali Solution, Preparation Thereof, And For The Use Of Nonspecific Immunostimulator
EP1985702A3 (en) 2000-12-08 2010-08-18 Coley Pharmaceutical GmbH CPG-like nucleic acids and methods of use thereof
AU2002248185A1 (en) 2000-12-14 2002-07-16 Coley Pharmaceutical Group, Inc. Inhibition of angiogenesis by nucleic acids
US20030185848A1 (en) * 2000-12-15 2003-10-02 Board Of Regents, The University Of Texas System Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of Chlamydia psittaci
EP1364010B1 (en) * 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
CA2439428C (en) 2001-04-17 2012-01-24 Chiron Corporation Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
US20030096417A1 (en) * 2001-06-01 2003-05-22 Fischer Laurent Bernard Vaccination against feline immunodeficiency virus
US7547551B2 (en) * 2001-06-21 2009-06-16 University Of Antwerp. Transfection of eukaryontic cells with linear polynucleotides by electroporation
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
EP2423335B1 (en) * 2001-06-21 2014-05-14 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same
AU2002318944A1 (en) 2001-08-01 2003-02-17 Coley Pharmaceutical Gmbh Methods and compositions relating to plasmacytoid dendritic cells
EP1501359A4 (en) * 2001-08-03 2007-04-18 Celldex Therapeutics Inc Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
US20030133988A1 (en) * 2001-08-07 2003-07-17 Fearon Karen L. Immunomodulatory compositions, formulations, and methods for use thereof
US7604955B2 (en) * 2001-08-13 2009-10-20 Swey-Shen Alex Chen Immunoglobulin E vaccines and methods of use thereof
AU2002361468A1 (en) * 2001-08-14 2003-03-18 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Method for rapid generation of mature dendritic cells
SG177000A1 (en) * 2001-08-17 2012-01-30 Coley Pharm Gmbh Combination motif immune stimulatory oligonucleotides with improved activity
AU2002324909A1 (en) * 2001-09-07 2003-03-24 Baylor College Of Medicine Linear dna fragments for gene expression
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
AR045702A1 (en) * 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
BR0213097A (en) 2001-10-05 2005-02-01 Coley Pharm Gmbh Toll-like receptor 3 signaling agonists and antagonists
US20030139364A1 (en) * 2001-10-12 2003-07-24 University Of Iowa Research Foundation Methods and products for enhancing immune responses using imidazoquinoline compounds
US7544669B2 (en) * 2001-11-21 2009-06-09 The Board Of Trustees Of The Leland Stanford Junior University Polynucleotide therapy
TW200303759A (en) * 2001-11-27 2003-09-16 Schering Corp Methods for treating cancer
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20030194079A1 (en) * 2002-04-15 2003-10-16 Scott James D. Method and system for remotely delivering identification tags
CA2388049A1 (en) 2002-05-30 2003-11-30 Immunotech S.A. Immunostimulatory oligonucleotides and uses thereof
US20040009949A1 (en) * 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
AU2003267986A1 (en) * 2002-07-03 2004-01-23 Depuy Mitek, Inc. Vaccines to induce mucosal immunity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000061151A2 (en) * 1999-04-12 2000-10-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response
WO2001051500A1 (en) * 2000-01-14 2001-07-19 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligodeoxynucleotide and its use to induce an immune response

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871732B2 (en) 2002-12-23 2014-10-28 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US9422564B2 (en) 2002-12-23 2016-08-23 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same

Also Published As

Publication number Publication date
US7354909B2 (en) 2008-04-08
WO2003020884A2 (en) 2003-03-13
US20080241176A1 (en) 2008-10-02
AU2002361468A1 (en) 2003-03-18
US20040241841A1 (en) 2004-12-02
US7959934B2 (en) 2011-06-14

Similar Documents

Publication Publication Date Title
WO2003020884A3 (en) Method for rapid generation of mature dendritic cells
AU2001282123A1 (en) Method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells
HK1063528A1 (en) Proton conducting membrane, method for producing the same, and fuel cell using the same
EP2298927A3 (en) Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP1276486B8 (en) Joint repair using mesenchymal stem cells
WO2000046383A8 (en) Method of modulating metabolite biosynthesis in recombinant cells
IL163180A (en) Expansion of renewable hematopoietic stem cell populations and use thereof
EP0765386A4 (en) Methods for in vivo t cell activation by antigen-pulsed dendritic cells
WO2009092005A3 (en) Methods of generating cardiomyocytes and cardiac progenitors and compositions
ATE388237T1 (en) DENDRITIC CELL HYBRIDS
AU2003272877A1 (en) Electrode for fuel cell, fuel cell including the electrode and process for producing the same
AU1152397A (en) Methods for in vivo t cell activation by antigen-pulsed dendritic cells
WO1999021976A3 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
WO2004008286A3 (en) Arrangements and methods for treating a subject
MY121471A (en) Process for the preparation of hydroxy methylthiobutyric acid esters
HK1034001A1 (en) Nickel electrode for alkali storage battery, method of producing nickel electrode for alkali storagebattery, and alkali storage battery.
WO2003082757A3 (en) Methods of modifying fibers
EP1229111A3 (en) Cultured cells of Ficus stipulata thunb. (= Ficus thunbergii) and a method for culturing tissues of the Ficus stipulata by using said cultured cells
AU2002221814A1 (en) Cell constructs which can be obtained from mesenschymal stem cells and cells derivable therefrom and the use thereof
WO2004072262A3 (en) Cultured cd14+ antigen presenting cells
AU2002243895A1 (en) Method for generating hydrogen for fuel cells
AU1848401A (en) A novel method to produce human natural interferon-alpha
AU7009600A (en) Method for obtaining dendritic cells, resulting dendritic cells and uses thereof for clinical purposes
WO2001090316A3 (en) Human circulating dendritic cell compositions and methods
WO1998003669A3 (en) Vectors for inhibiting hiv and tumor growth

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG US

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10486755

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP